Published Date: 04/11/2011
Category: Emerging Technologies & Scientific Research
BioMarin Pharmaceutical Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.Features:Detailed information on BioMarin Pharmaceutical Inc. required for business and competitor intelligence needsA study of the major internal and external factors affecting BioMarin Pharmaceutical Inc. in the form of a SWOT analysisAn in-depth view of the business model of BioMarin Pharmaceutical Inc. including a breakdown and examination of key business segmentsIntelligence on BioMarin Pharmaceutical Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisorsNews about BioMarin Pharmaceutical Inc., such as business expansion, restructuring, and contract winsLarge number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to Purchase: Gain understanding of BioMarin Pharmaceutical Inc. and the factors that influence its strategies Track strategic initiatives of the company and latest corporate news and actions Assess BioMarin Pharmaceutical Inc. as a prospective partner, vendor or supplier Support sales activities by understanding your customers' businesses better Stay up to date on BioMarin Pharmaceutical Inc.’s business structure, strategy and prospects
Biomarin Pharmaceuticals
BioMarin Pharmaceutical (BioMarin) is engaged in development and commercialization of biopharmaceuticals. The company select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market. The company primarily operates in the US. It is headquartered in Novato, California and employed 871 people as of January 21, 2011. The company recorded revenues of $376.3 million during the financial year (FY) ended December 2010, an increase of 15.9% over FY2009. The operating profit of the company was $0.5 million during FY2010, a decrease of 96.7% over FY2009. The net profit was $205.8 million in FY2010, as compared to a net loss of $0.5 million in FY2009.